1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Escherichia coli Infections - Drugs In Development, 2022, provides an overview of the Escherichia coli Infections (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Escherichia coli (E. coli) bacteria normally live in the intestines of healthy people and animals. Escherichia coli infections are caused by coming into contact with the feces, or stool, of humans or animals or drink water or eat food that has been contaminated by feces. Symptoms include diarrhea, which may range from mild and watery to severe and bloody, abdominal cramping, pain or tenderness, nausea and vomiting. The predisposing factors include age, weakened immune systems and eating certain types of food like undercooked hamburger, unpasteurized milk, apple juice or cider and soft cheeses made from raw milk. Treatment includes antibiotics and healthy life style.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Escherichia coli Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Escherichia coli Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Escherichia coli Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Escherichia coli Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 30, 18 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 6 and 13 molecules, respectively.
Escherichia coli Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Escherichia coli Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Escherichia coli Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Escherichia coli Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Escherichia coli Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Escherichia coli Infections (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Escherichia coli Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Escherichia coli Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Escherichia coli Infections - Overview
- Escherichia coli Infections - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Escherichia coli Infections - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Escherichia coli Infections - Companies Involved in Therapeutics Development
- Escherichia coli Infections - Drug Profiles
- Escherichia coli Infections - Dormant Projects
- Escherichia coli Infections - Discontinued Products
- Escherichia coli Infections - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Escherichia coli Infections, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Escherichia coli Infections - Dormant Projects, 2022
- Escherichia coli Infections - Discontinued Products, 2022
- Number of Products under Development for Escherichia coli Infections, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- ABAC Therapeutics SA
- Affilogic SAS
- Alterity Therapeutics Ltd
- Armata Pharmaceuticals Inc
- AstraZeneca Plc
- Atterx Biotherapeutics Inc
- BB100 LLC
- Biomendics LLC
- Bugworks Research Inc
- ContraFect Corp
- Dong-A ST Co Ltd
- Eligo Bioscience SA
- Entasis Therapeutics Holdings Inc
- EveliQure Biotechnologies GmbH
- F. Hoffmann-La Roche Ltd
- Forge Therapeutics Inc
- GlyProVac ApS
- Immunethep SA
- Johnson & Johnson
- Linnaeus Bioscience Inc
- Meiji Seika Pharma Co Ltd
- Melinta Therapeutics Inc
- Merck & Co Inc
- MetalloBio Ltd
- Microbiotix Inc
- Navigen Inc
- Nektr Technologies Ltd
- Neoculi Pty Ltd
- Northern Antibiotics Oy
- Nosopharm SAS
- Novabiotics Ltd
- Ostrich Pharma USA Inc
- Oxford Drug Design Ltd
- Pedanius Therapeutics Ltd
- PGTx Ltd
- Phico Therapeutics Ltd
- Planet Biotechnology Inc
- Protein Potential LLC
- Pylum Biosciences Inc
- Recce Pharmaceuticals Ltd
- RemAb Therapeutics SL
- Shanghai Space Peptides Pharmaceutical Co Ltd
- SNIPR Biome ApS
- Spero Therapeutics Inc
- Spexis AG
- Syntiron LLC
- VenatoRx Pharmaceuticals Inc
- Venus Medicine Research Centre
